Differential activation of MAPK and PI3K/AKT/mTOR pathways and IGF1R expression in gastrointestinal stromal tumors

Anticancer Research

Volumn 31, Issue 9, 2011, Pages 3019-3025

  Rios Moreno M J ^a   Jaramillo, S ^a   Diaz Delgado M ^b   Sanchez Leon M ^a   Trigo Sanchez I ^a   Polo Padillo, J ^c   Amerigo J ^d   González Cámpora, Ricardo ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^b Hospital de Merida   (Spain)

^c UNIVERSITY OF SEVILLE   (Spain)

^d Department of Pathology   (Spain)

Author keywords

CD117; Gastrointestinal stromal tumors (GISTs); Insulin like growth factor 1 receptor (IGF1R); PI3K Akt mTOR pathway; Ras Raf ERK MAPK pathway

Indexed keywords

INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN KINASE B; PROTEIN S6; S6 KINASE; SOMATOMEDIN C RECEPTOR; STEM CELL FACTOR RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; EXON; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE ACTIVATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

BASE SEQUENCE; DNA PRIMERS; ENZYME ACTIVATION; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASES; RECEPTOR, IGF TYPE 1;

EID: 80051619030     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Dematteo RP, Heinrich MC, El-Rifai WM and Demetri G: Clinical mamagement of gastrointestinal tromal tumor: before and after STI-571. Hum Pathol 33: 466-477, 2002. (Pubitemid 34747865)
2. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S and Fletcher JA: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21: 4342-4349, 2003. (Pubitemid 46621810)
3. Debiec-Rychter M, Wasag B, Stul M, De Wever I, Van Oosterom A, Hagemeijer A and Sciot R: Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity. J Pathol 202: 430-438, 2004. (Pubitemid 38456161)
4. Debiec-Rychter M: Sunitinib-a new approach following failure of imatinib in patients with advanced gastrointestinal stromal tumor. Nat Clin Pract Oncol 4: 342-343, 2007.
5. Lasota J and Miettinen M: Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology 53: 245-266, 2008.
6. Corless CL and Heinrich MC: Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol 3: 557-586, 2008. (Pubitemid 351488293)
7. Duensing A, Medeiros F, McConarty B, Joseph NE, Panigrahy D, Singer S, Fletcher CD, Demetri GD and Fletcher JA: Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene 23: 3999-4006, 2004. (Pubitemid 38747928)
8. Bauer S, Duensing A, Demetri GB and Fletcher JA: KIT oncogenes signalling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway. Oncogene 26: 7560-7568, 2007. (Pubitemid 350207707)
9. Yang Y, Ikezoe T, Nishioka C, Taguchi T, Zhu WG, Koeffler HP and Taguchi H: ZD6474 induces growth arrest and apoptosis of GIST-T1 cells, which is enhanced by concomitant use of sunitinib. Cancer Sci 97: 1404-1409, 2006. (Pubitemid 44614994)
10. Ikezoe T, Nishioka C, Tasaka T, Yang Y, Komatsu N, Togitani K, Koeffler HP and Taguchi H: The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling. Mol Cancer Ther 5: 2522-2530, 2006. (Pubitemid 44650916)
11. Ou WB, Zhu MJ, Demetri GD, Fletcher CD and Fletcher JA: Protein kinase C-theta regulates KIT expression and proliferation in gastrointestinal stromal tumors. Oncogene 27: 5624-5634, 2008.
12. Sàpi Z, Füle T, Hadju M, Matolesy A, Moskovszky L, Márk A, Sebestyén A and Bodoky G: The activated targets of mTOR signalling pathway are characteristic for PDGFRA mutant and wild-type rather than Kit mutant GISTs. Diagn Mol Pathol 20(1): 22-33, 2011
13. Kang HJ, Nam SW, Kim H, Rhee H, Kim NG, Kim H, Hyung WJ, Noh SH, Kim JH, Yun CO, Liu ET and Kim H: Correlation of KIT and platelet- derived growth factor receptor α mutations with gene activation and expression profiles in gastrointestinal stromal tumors. Oncogene 24: 1066-1074, 2005. (Pubitemid 40313883)
14. Braconi C, Bracci R, Bearzi I, Bianchi F, Sabato S, Mandolesi A, Belvederesi L, Cascinu S, Valeri N, Cellerino R. Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients. Ann Oncol 19: 1293-1298, 2008. (Pubitemid 351911960)
15. Tarn C, Rink L, Merkel E, Flieder D, Pathak H, Koumbi D, Testa JR, Eisenberg B, von Mehren M and Godwin AK: Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci USA 105: 8387-8392, 2008. (Pubitemid 351904765)
16. Agaram NP, Laquaglia MP, Ustun B, Guo T, Wong GC, Socci ND, Maki RG, Dematteo RP, Besmer P and Antonescu CR: Molecular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer Res 14: 3204-3215, 2008.
17. Pantaleo MA, Astolfi A, Di Battista M, Heinrich MC, Paterini P, Scotlandi K, Santini D, Catena F, Manara MC, Nannini M, Maleddu A,Saponara M, Lolli C and Formica S Biasco G: The activated targets of mTOR signaling pathway are characteristic for PDGFRA mutant and wild-type rather than KIT mutant GISTs. Diagn Mol Pathol 20: 22-33, 2011.
18. Janeway KA, Zhu MJ, Barretina J, Zhu MJ, Barretina J, Perez-Atayde A, Demetri GD and Fletcher JA: Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGFIR genomic amplification. Int J Cancer 127: 2718-2722, 2010.
19. Tao Y, Pinzi V, Bourhis J and Deutsch E: Mechanisms of diseases: signalling of the insulin-like growth factor 1 receptor pathway-therapeutic perspectives in cancer. Nature Clin Pract Oncology 4: 591-602, 2007. (Pubitemid 47534758)
20. Kappel CC, Velez-Yanguas MC, Hirschfeld S and Helman LJ: Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth. Cancer Res 54: 2803-2807, 1994. (Pubitemid 24173778)
21. Scotlandi K, Benini S, Sarti M, Serra M, Lollini P-L, Maurici D, Picci P, Triche TJ and Baldini N: Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res 56: 4570-4574, 1996. (Pubitemid 26338048)
22. Friedrichs N, Küchler J, Endl E, Koch A, Czerwitzki J, Wurst P, Metzger D, Schulte JH, Holst MI, Heukamp LC, Larsson O, Tanaka S, Kawai A, Wardelmann E, Buettner R, Pietsch T and Hartmann W: Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma. J Pathol 216: 428-439, 2008.
23. Van der Ven LT, Roholl PJ, Gloudemans T, Van Buul-Offers SC, Welters MJ, Bladergroen BA, Faber JA, Sussenbach JS and Den Otter W: Expression of insulin-like growth factors (IGFs), their receptors and IGF binding protein-3 in normal, benign and malignant smooth muscle tissues. Br J Cancer 75: 1631-1640, 1997 (Pubitemid 27229054)
24. Xie Y, Skytting B, Nilsson G, Brodin B and Larsson O: Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype. Cancer Res 59: 3588-3591, 1999. (Pubitemid 29381857)
25. Ahlen J, Wejde J, Brosjo O, von Rosen A, Weng WH, Girnita L, Larsson O and Larsson C: Insulin-like growth factor type 1 receptor expression correlates to good prognosis in highly malignant soft tissue sarcoma. Clin Cancer Res 11: 206-216, 2005 (Pubitemid 40075797)
26. Zhan S, Shapiro DN and Helman LI: Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. J Clin Invest 94: 445-448, 1994. (Pubitemid 24218124)
27. Shapiro DN, Jones BG, Shapiro LH, Dias P and Houghton PJ: Antisense mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma. J Clin Invest 94: 1235-1242, 1994. (Pubitemid 24286468)
28. Liu X, Turbyville T, Fritz A and Whitesell L: Inhibition of insulin-like growth factor I receptor expression in neuroblastoma cells induces the regression of established tumors in mice. Cancer Res 58: 5432-5438, 1998. (Pubitemid 28551127)
29. Busund LT, Ow KT, Russell P, Crowe PJ and Yang JL: Expression of insulin-like growth factor mitogenic signals in adult soft-tissue sarcomas: significant correlation with malignant potential. Virchows Arch 444: 142-148, 2004. (Pubitemid 38315291)
30. Fletcher CDM, Berman JJ, Corless C, Gorstein F, Lasota J, Jjack Longley B, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH and Weiss SW: Diagnosis of gastrointestinal stromal tumors: consensus approach. Hum Pathol 33: 459-465, 2002. (Pubitemid 34747864)
31. Miettinen M, EL-Rifai W, Sobin LH and Lasota J: Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: A Review. Human Pathol 33: 478-483, 2002. (Pubitemid 34747866)
32. Duensing A, Joseph NE, Medeiros F, Smith F, Hornick JL, Heinrich MC, Corless CL, Demetri GD, Fletcher CD and Fletcher JA: Protein kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs). Cancer Res 64: 5127-5133, 2004.
33. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA, Demetri GD, Fletcher CD and Fletcher JA: KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61: 8118-8121, 2001. (Pubitemid 33091601)
34. Rossi F, Ehlers I, Agosti V, Socci ND, Viale A, Sommer G, Yozgat Y, Manova K, Antonescu CR and Besmer P: Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor. Proc Natl Acad Sci USA 103: 12843-12848, 2006. (Pubitemid 44298649)
35. Walters DK, Goss VL, Stoffregen EP, Gu TL, Lee K, Nardone J, McGreevey L, Heinrich MC, Deininger MW, Polakiewicz R and Druker BJ: Phosphoproteomic analysis of AML cell lines identifies leukemic oncogenes. Leuk Res 30: 1097-1104, 2006. (Pubitemid 44055977)
36. Birkenkamp KU, Geugien M, Lemmink HH, Kruijer W and Vellenga E: Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts. Leukemia 15: 1923-1931, 2001.
37. Paner GP, Silberman S, Hartman G, Micetich KC, Aranha GV and Alkan S: Analysis of signal transducer and activator of transcription 3 (STAT3) in gastrointestinal stromal tumors. Anticancer Res 23(3B): 2253-2260, 2003. (Pubitemid 36897088)
38. Martinho O, Gouveia A, Viana-Pereira M, Silva P, Pimenta A, Reis RM and Lopes JM: Low frequency of MAP kinase pathway alterations in KIT and PDGFRA wild-type GISTs. Histopathology 55(1): 53-62, 2009.
39. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S and Fletcher JA: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumors. J Clin Oncol 21: 4342-4349, 2003. (Pubitemid 46621810)
40. Zhu MJ, Ou WB, Fletcher CD, Cohen PS, Demetri GD and Fletcher JA: KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance. Oncogene 26: 6386-6395, 2007. (Pubitemid 47494217)